Investigator-sponsored research support program

AVEO Oncology is committed to supporting investigator-sponsored research that contributes to the scientific and medical understanding of our products and relevant disease areas, and which enhances the practice of medicine, ultimately improving patient care.

• Investigator Sponsored Trial (IST) refers to submission of an unsolicited clinical trial proposed and sponsored by an investigator at a hospital, medical center, medical school, private foundation, private practice, group practice, or government-sponsored research network
• IST submissions are accepted on a rolling basis. An internal review committee evaluates the IST submission based on certain criteria, such as scientific merit, safety, legal and ethical considerations, financial commitment, and alignment with AVEO’s overall strategy
• AVEO Oncology may withdraw support if a Sponsor-Investigator fails to comply with applicable legal or regulatory obligations or provides false or misleading information in the submission

IST areas of interest

• Combination studies with novel agents being developed for the treatment of various cancers
• Select patient groups with solid tumors where there exists both a high unmet need and rationale for VEGF inhibition
• Biomarker-driven studies using immunological, histopathological, or genetic evaluations of disease to identify patients appropriate for treatment
• Studies assessing optimal sequencing of treatment in therapeutic areas of interest to maximize response, treatment duration, and/or safety
• Real-world data analysis of patient experience with tivozanib relative to other available small molecule TKIs/mTOR inhibitors, HIF2A, and checkpoint inhibitors by prognosis, line of therapy, duration of usage, and/or safety. Proposals should describe the expected number of patient records available for analysis